Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines
暂无分享,去创建一个
D. Tscharke | J. Sidney | A. Sette | J. Yewdell | J. Bennink | G. Karupiah | Jie Zhou | T. Palmore | K. Irvine | S. Haeryfar | S. Williams
[1] J. Marchal. Infectious Ectromelia. A hitherto Undescribed Virus Disease of Mice. , 1930 .
[2] R. F. Parker,et al. FURTHER STUDIES OF THE INFECTIOUS UNIT OF VACCINIA , 1941, The Journal of experimental medicine.
[3] F. Burnet,et al. The relationship between the virus of infectious ectromelia of mice and vaccinia virus. , 1946, Journal of immunology.
[4] F. Fenner,et al. Studies in infectious ectromelia of mice; immunization of mice against ectromelia with living vaccinia virus. , 1947, The Australian journal of experimental biology and medical science.
[5] F. Fenner,et al. The pathogenesis of the acute exanthems; an interpretation based on experimental investigations with mousepox; infectious ectromelia of mice. , 1948, Lancet.
[6] F. Fenner,et al. Mouse-pox; infectious ectromelia of mice; a review. , 1949, Journal of immunology.
[7] R. Blanden. MECHANISMS OF RECOVERY FROM A GENERALIZED VIRAL INFECTION: MOUSEPOX , 1971, The Journal of experimental medicine.
[8] B. Moss,et al. Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques , 1985, Molecular and cellular biology.
[9] B. Moss,et al. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype , 1985, Nature.
[10] F. Fenner. Smallpox and its eradication , 1988 .
[11] E. Coligan. Current protocols in immunology , 1991 .
[12] B. Moss,et al. Sequence analysis, expression, and deletion of a vaccinia virus gene encoding a homolog of profilin, a eukaryotic actin-binding protein , 1991, Journal of virology.
[13] Li Wu,et al. The surface phenotype of dendritic cells purified from mouse thymus and spleen: investigation of the CD8 expression by a subpopulation of dendritic cells , 1992, The Journal of experimental medicine.
[14] B. Moss,et al. Nonreplicating vaccinia vector efficiently expresses recombinant genes. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[15] G. Karupiah,et al. Importance of interferons in recovery from mousepox , 1993, Journal of virology.
[16] J. Sidney,et al. Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays. , 1994, Molecular immunology.
[17] A. Vitiello,et al. Immunodominance analysis of CTL responses to influenza PR8 virus reveals two new dominant and subdominant Kb-restricted epitopes. , 1996, Journal of immunology.
[18] G. Karupiah,et al. Different roles for CD4+ and CD8+ T lymphocytes and macrophage subsets in the control of a generalized virus infection , 1996, Journal of virology.
[19] C. Mims. The Pathogenesis of the Acute Exanthems , 1996 .
[20] B. Moss,et al. Vaccinia virus A17L open reading frame encodes an essential component of nascent viral membranes that is required to initiate morphogenesis , 1996, Journal of virology.
[21] K. Rock,et al. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. , 1997, Journal of immunology.
[22] F. Falkner,et al. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. , 1998, Virology.
[23] J. Yewdell,et al. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. , 1999, Annual review of immunology.
[24] J. Sidney,et al. Conserved MHC Class I Peptide Binding Motif Between Humans and Rhesus Macaques1 , 2000, The Journal of Immunology.
[25] J. Ramírez,et al. Biology of Attenuated Modified Vaccinia Virus Ankara Recombinant Vector in Mice: Virus Fate and Activation of B- and T-Cell Immune Responses in Comparison with the Western Reserve Strain and Advantages as a Vaccine , 2000, Journal of Virology.
[26] D. Smee,et al. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. , 2000, The Journal of infectious diseases.
[27] W Chen,et al. Dissecting the multifactorial causes of immunodominance in class I-restricted T cell responses to viruses. , 2000, Immunity.
[28] S. Fields,et al. Genome-wide analysis of vaccinia virus protein-protein interactions. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[29] John Sidney,et al. Measurement of MHC/Peptide Interactions by Gel Filtration , 1999, Current protocols in immunology.
[30] Anthony S. Fauci,et al. Bioterrorism: A clear and present danger , 2001, Nature Medicine.
[31] J. Yewdell,et al. Inhibitory Effects of Cytomegalovirus Proteins US2 and US11 Point to Contributions from Direct Priming and Cross-Priming in Induction of Vaccinia Virus-Specific CD8+ T Cells , 2002, The Journal of Immunology.
[32] A. Rothman,et al. Primary induction of human CD8+ cytotoxic T lymphocytes and interferon-gamma-producing T cells after smallpox vaccination. , 2002, The Journal of infectious diseases.
[33] Hans-Georg Rammensee,et al. Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[34] G. McFadden,et al. Poxviruses and immune evasion. , 2003, Annual review of immunology.
[35] John Cruz,et al. Quantitation of CD8+ T Cell Responses to Newly Identified HLA-A*0201–restricted T Cell Epitopes Conserved Among Vaccinia and Variola (Smallpox) Viruses , 2003, The Journal of experimental medicine.
[36] Rachel L. Roper,et al. Poxvirus Orthologous Clusters: toward Defining the Minimum Essential Poxvirus Genome , 2003, Journal of Virology.
[37] J. Berzofsky,et al. Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[38] G. Karupiah,et al. Polarized type 1 cytokine response and cell-mediated immunity determine genetic resistance to mousepox , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[39] I. M. Belyakov,et al. Protection against Lethal Vaccinia Virus Challenge in HLA-A2 Transgenic Mice by Immunization with a Single CD8+ T-Cell Peptide Epitope of Vaccinia and Variola Viruses , 2004, Journal of Virology.
[40] B. Graham,et al. Modified vaccinia Ankara: potential as an alternative smallpox vaccine. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[41] G. Carcelain,et al. Distinct Time Effects of Vaccination on Long-Term Proliferative and IFN-γ–producing T Cell Memory to Smallpox in Humans , 2004, The Journal of experimental medicine.
[42] Aaron J. Johnson,et al. Cellular and Humoral Immunity against Vaccinia Virus Infection of Mice 1 , 2004, The Journal of Immunology.
[43] P. Earl,et al. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[44] P. Earl,et al. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox , 2004, Nature.